16-Nov-2023    Noxopharm 2023 AGM Corporate Presentation  
 
16-Oct-2023    Noxopharm talks partnership with Hudson Institute of Medical Research  
 
2-Jun-2023    Noxopharm hails new Sofra™ drug inflammation results  
 
17-Nov-2022    Noxopharm 2022 AGM Corporate Presentation  
 
4-Oct-2022    Ausbiz interview regarding pancreatic cancer research  
 
14-Sep-2022    Noxopharm reveals encouraging new pancreatic cancer preclinical study data  
 
7-Jun-2022    Noxopharm New Corporate Presentation June 2022  
 
25-Mar-2022    Noxopharm CEO talks Veyonda Orphan Drug Designation from US FDA  
 
11-Jan-2022    Noxopharm Presents at HC Wainright BioConnect Conference 10-13 January 2022  
 
22-Dec-2021    Noxopharm Discusses the Subsidiary Pharmorage  
 
17-Nov-2021    Noxopharm 2021 AGM Corporate Presentation  
 
9-Sep-2021    Noxopharm Updated Corporate Presentation  
 
9-Sep-2021    Noxopharm ASX:NOX CEO Dr Graham Kelly on 6PR, 2GB and 3AW Bulls N' Bears  
 
24-Aug-2021    Noxopharm Talks to Proactive Investors about NOXCOVID trial Phase 1 results  
 
11-Aug-2021    Presentation at Proactive Investors Life Sciences Webinar 10 August 2021  
 
5-Jul-2021    Noxopharm Presents at Broker Briefing 1 July 2021  
 
30-Jun-2021    Noxopharm Presents at the Stockhead V-CON Biotech virtual event  
 
28-Jun-2021    Noxopharm Corporate Presentation  
 
20-May-2021    Noxopharm’s CEO Dr Graham Kelly outlines Noxopharm’s ‘Four Pillars’ oncology strategy  
 
27-Apr-2021    CEO Dr Graham Kelly speaks with The Inside Network  
 
23-Apr-2021    Interview with Proactive Investors: Noxopharm CEO encouraged by positive interim data from NOXCOVID trial  
 
7-Apr-2021    Noxopharm (ASX:NOX) CEO Dr Graham Kelly presents to the Switzer Small & Micro Cap Conference March 2021  
 
29-Mar-2021    Corporate Presentation for Switzer Virtual Investor Day  
 
24-Mar-2021    The CEO Masterclass - Noxopharm CEO Dr Graham Kelly speaks with Peter Switzer  
 
18-Mar-2021    Noxopharm Presents to the ASX Small & Mid Cap Conference March 2021  
 
18-Mar-2021    Noxopharm with Proactive Investors at the ASX Small and Mid-Cap Conference March 2021  

Noxopharm with Proactive at the ASX Small and Mid-Cap Conference (proactiveinvestors.com.au)

 		 
16-Mar-2021    ASX Small-Mid Cap Conference Corporate Presentation  
 
5-Mar-2021    Noxopharm Presents to H.C. Wainwright Global Conference  
 
23-Feb-2021    Noxopharm Updated Corporate Presentation February-March 2021  
 
12-Feb-2021    Noxopharm study finds its drug improves prostate cancer survival rates  
 
1-Feb-2021    Noxopharm (ASX:NOX) - Hidden Gems Webinar Presentation - ShareCafe  
 
28-Jan-2021    Noxopharm To Present to ShareCafe Hidden Gems Webinar  
 
9-Dec-2020    Noxopharm Limited (ASX:NOX) CEO and Managing Director Dr Graham Kelly gives an update on the company and its clinical trials.  
 
8-Dec-2020    Noxopharm Corporate Presentation December Investor Webinar  
 
7-Dec-2020    The Market Herald Deal Room Interview with Noxopharm CEO and Managing Director Dr Graham Kelly  
 
2-Dec-2020    Switzer Small & Micro Cap Virtual Investor Day 2020  
 
17-Nov-2020    Noxopharm 2020 AGM Corporate Update  
 
13-Nov-2020    CEO Dr Graham Kelly discusses the announcement of independent validation of Noxopharm's DARRT cancer therapy with TCN TV  
 
9-Oct-2020    Noxopharm CMO discusses first patient treated in NOXCOVID trial  
 
21-Sep-2020    Noxopharm Corporate Presentation September 2020  
 
19-Aug-2020    Pitt Street Research Noxopharm CEO interview August 2020  
 
14-Aug-2020    Noxopharm August 2020 EGM Corporate Presentation  
 
23-Jul-2020    FNN interview: Noxopharm Discusses Converting Cold Cancer Tumours to Hot Tumours  
 
8-Jul-2020    Reach Markets "Meet the CEO's" Virtual Event July 8, 2020 Recording  
 
8-Jul-2020    Corporate Presentation for the Reach Markets Virtual Event  
 
5-Jun-2020    Webcast Overview of ASCO 2020 Annual Meeting NOX Posters  
 
2-Apr-2020    Updated Noxopharm Virtual Roadshow Corporate Presentation  
 
31-Mar-2020    Noxopharm Virtual Roadshow Corporate Presentation  
 
22-Mar-2020    Veyonda® Mode of Action  
 
27-Feb-2020    Noxopharm Corporate Presentation February 2020  
 
26-Feb-2020    Noxopharm (ASX:NOX) LuPIN trial in prostate cancer  
 
29-Jan-2020    Noxopharm Non-Deal Roadshow Presentation  
 
31-Dec-2019    Veyonda® - Boosting the effectiveness of radiotherapy  
 
20-Dec-2019    DARRT-1 Clinical Data Webinar  
 
3-Dec-2019    NOXOPHARM DARRT-1 Interview Dec 2, 2019  
 
20-Nov-2019    NOX 2019 AGM webcast  
 
20-Nov-2019    Noxopharm 2019 AGM Corporate Presentations  
 
22-Oct-2019    NOX and Nyrada TechKnow Invest Roadshow Presentations  
 
2-Oct-2019    Noxopharm looks at treating prostate cancer with Veyonda® in the LuPIN trial  
 
16-Sep-2019    NOX EGM Chairman's Address and Presentation  
 
28-Aug-2019    CEO Interview: Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment – DARRT-1 Interim Results  
 
9-Aug-2019    Noxopharm (ASX:NOX) 3-year listing anniversary update  
 
7-Aug-2019    Noxopharm August 2019 Corporate Presentation  
 
2-Jul-2019    Oral Presentation interim LuPIN-1 trial results given by Assoc. Professor Louise Emmett at SNMMI 2019 Annual Meeting, Anaheim CA  
 
27-Jun-2019    Noxopharm CEO & CMO Dr Greg van Wyk spoke recently with Karen Jagoda on the Empowered Patient Podcast about the increasing interest in combining therapies to treat prostate cancer as well as cancer types.  
 
6-Jun-2019    Noxopharm Corporate Presentation June 2019  
 
8-May-2019    Switzer Daily: How a biotech company could change cancer treatment  
 
2-May-2019    CEO Interview DARRT Program 6-month Interim Results  
 
28-Mar-2019    Noxopharm Ausbiotech Asia Series March 2019 Presentation  
 
5-Mar-2019    March 2019 Corporate Presentation  
 
26-Feb-2019    FNN - Shaw & Partners Investor Event 26.2.19  
 
6-Feb-2019    St Vincent's Hospital Principal Investigator Discussed LuPIN-1 Study  
 
6-Feb-2019    FNN interview with Nox Chief Medical Officer on Interim Data  
 
27-Nov-2018    2018 Annual General Meeting podcast  
 
21-Nov-2018    NOX 2018 AGM Presentations  
 
21-Aug-2018    Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney  
 
20-Aug-2018    Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials  
 
14-Aug-2018    NOX Corporate Presentation FNN-Shaw&Partners Investor Event  
 
7-Jun-2018    Noxopharm Corporate Presentation for Public Briefing  
 
7-May-2018    Noxopharm CEO Interview Updates the Company's Current Research and Development Program  
 
3-May-2018    Noxopharm CEO Interview on near-completed NOX66 chemotherapy trial CEP-1  
 
27-Apr-2018    Noxopharm CEO Interview with FNN on the Company's NOX66 and Radiotherapy Clinical Programs  
 
12-Mar-2018    Corporate Presentation - Post Interim Clinical Data Release  
 
6-Mar-2018    Noxopharm CEO talks to FNN about CEP-1 Clinical Study Interim Data from 2018 TAT Congress in Paris, March 5-7  
 
6-Dec-2017    NOX Open Briefing Corporate Presentation  
 
29-Nov-2017    Noxopharm Limited 2017 AGM Webcast, November 27, 2017  
 
27-Nov-2017    AGM Presentations  
 
6-Nov-2017    EGM Presentations  
 
19-Oct-2017    October 2017 Open Briefing Corporate Presentation  
 
8-Aug-2017    Noxopharm Corporate Presentation for 2017 ASX Growth Series Conference, Singapore August 21  
 
25-Jul-2017    New Corporate Presentation  
 
30-May-2017    New Corporate Presentation  
 
10-Apr-2017    Discovery of Idronoxil-C - NOX CEO explains  
 
10-Apr-2017    FNN Interview with NOX CEO Explaining Idronoxil-C Discovery  
 
28-Feb-2017    ASX The CEO Sessions - ASX Interview  
 
28-Feb-2017    ASX The CEO Sessions February 2017 Presentation  
 
21-Feb-2017    ASX CEO Presentation Feb 2017 slides  
 
15-Feb-2017    Upcoming Events and Presentations  
 
6-Feb-2017    Noxopharm (ASX:NOX) talks clinical trials and applications for ‘NOX66’  
 
22-Nov-2016    November 2016 Corporate Presentation  
 
22-Nov-2016    Corporate Presentation Providing Clinical Program Guidance  
 
20-Oct-2016    Corporate Presentation  
 
1-Jun-2016    Investor Roadshow Presentation